A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency (Harmony)

drug protocol number

TVTX-TVT058-301

drug sponsor

Travere Therapeutics, Inc. / CTI

drug study

Pegtibatinase

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Riyadh)

drug status

Ongoing

drug phase